Lates News

Recently, the chairman of the board of directors of the Danish pharmaceutical giant Novo Nordisk, Lars Fruergaard Jorgensen, highly praised the clear goals and systematic planning of the Chinese government in addressing chronic diseases, such as the "Healthy China 2030" Planning Outline issued by China. He emphasized that Novo Nordisk hopes to become a trusted long-term partner of the Chinese government in the field of medical health.